Navigation Links
The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnology's CYT003 for the Treatment of Allergic Asthma
Date:3/12/2013

ZURICH, March 13, 2013 /PRNewswire/ --

Cytos Biotechnology Ltd (SIX:CYTN) today announced the publication of the results from its phase 2a clinical trial with CYT003-QbG10 (CYT003), a first-in-class immune modulator in clinical development as a potential new treatment for allergic asthma. The data are published in the March issue of The Journal of Allergy and Clinical Immunology (JACI) in the article entitled "The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma" by Kai-Michael Beeh , MD, et al. (J Allergy Clin Immunol. 2013 Mar;131(3):866-874).

The article was selected for comment by the JACI Editors ("The Editors' Choice") under the heading "Get the balance right - therapeutic immune modulation in patients with allergic asthma" (J Allergy Clin Immunol. 2013 Mar; 131 (3):683).

The published study is a randomized, double-blind, placebo-controlled trial in patients with persistent allergic asthma requiring long-term treatment with inhaled corticosteroids (ICS). The study took place at five centers in Germany and recruited 63 patients who received 7 weekly to bi-weekly subcutaneous injections, with efficacy assessment during 12 weeks. ICS treatment was withdrawn in two steps from 100% to 50% to 0%. Clinical endpoints included asthma control determined by a validated questionnaire (ACQ), lung function objectively assessed by spirometry (FEV1), day and night-time asthma symptoms and use of relief medication. In addition inflammatory markers (exhaled nitric oxide and eosinophils in the peripheral blood) were evaluated. The study met all clinical endpoints. In patients treated with CYT003 their asthma control improved despite ICS withdrawal. In patients on placebo, the withdrawal of ICS, as expected, led to a worsening of the disease with a statistically significant and clinically important difference between treatment
'/>"/>

SOURCE Cytos Biotechnology Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 2012-2013 Michael E. DeBakey Journalism Awards Call for Entries
2. Clinical Immunology Society Appoints Vincent Bonagura, MD as Editor-in-Chief of the Journal of Clinical Immunology
3. Elsevier Announces the Launch of a New Journal: Methods in Oceanography
4. Glencoe Software Announces Extensive Design, Usability and Data DOI Upgrades for The Journal of Cell Biologys JCB DataViewer.
5. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
6. Elsevier Announces the Launch of a New Journal: Journal of Forensic Radiology and Imaging
7. Officials Find Bed Bugs in Wall Street Journal; Spray For Bed Bugs Offers Advice How to Safely Counter Possible Bed Bug Comeback
8. Major Diabetes Peer-Review Journal Publishes Postive Results Of Ultradian Diagnostics Human Pilot Study
9. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
10. Springer to publish new open access journal with the Korean Society for Micro and Nano Systems
11. Elsevier Offers Entire Collection of Journals and Books to Innovators in Developing Countries Through the Access to Research for Development and Innovation (ARDI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The global market for molecular diagnostics is expected to ... new study by Grand View Research, Inc. Growing demand ... of advanced cancer diagnostic technologies are expected to be ... years. Moreover, the growing global base of geriatric population ... triggering lifestyle habits such as smoking and excessive alcohol ...
(Date:7/31/2014)... 31, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues, today ... results will be released on Thursday, August 7, 2014, ... and live webcast at 4:30 p.m. ET that afternoon. ...
(Date:7/31/2014)... July 31, 2014 Boston’s Adult Stem ... flush with innovative adult stem cell biotechnologies. Currently ... and has three additional patent applications currently under examination ... patented inventions address two of the most vexing problems ... Adult stem cells are difficult to identify; and ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
Breaking Biology Technology:Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 2The Adult Stem Cell Technology Center, LLC Launches A Marketing Campaign To License Adult Stem Cell Biotechnologies 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6
... Adam Chasse, RxTrials, vice president of Corporate Development, ... society, during ceremonies at the University of North Carolina ... Chasse earned a Master of Healthcare Administration degree ... Health at UNC-CH. He has a long and distinguished ...
... 2012 AMRI (NASDAQ: AMRI ) announced ... functions. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ... teams are being combined into one functional sales organization, ... promoted to Vice President, Business Development, North America. This ...
... 2012  Today the Colorado legislature recognized Donor Alliance ... and tissue donation in Colorado. Members of Donor ... community partners accepted the resolution, sponsored by Senator ... Dan Pabon (D-Denver) and Representative Carole Murray (R-Castle ...
Cached Biology Technology:Adam Chasse Inducted Into Delta Omega Public Health Honorary Society 2AMRI Strengthens Business Development and Marketing Groups 2AMRI Strengthens Business Development and Marketing Groups 3Donor Alliance Honored By Colorado Legislature In Observation Of National Donate Life Month 2
(Date:7/31/2014)... Census Bureau, Latinos are the largest minority group in ... Approximately one-third of Latinos are obese and are 1.2 ... Whites. , NYU College of Nursing student researcher ... identify the factors that contribute to this problem by ... on food patterns in Latina women recently published in ...
(Date:7/31/2014)... of the roughly 156,000 gas stations across the ... parts of underground gas storage tankscorrosion that could ... a source of drinking water. In recent years, ... rapidly corroding gas storage tank components such as ... use of gasoline-ethanol blends and the presence of ...
(Date:7/31/2014)... An experimental vaccine protected 100 percent of animal models ... difficile , which causes an intestinal disease that kills ... of print in Infection and Immunity . ... and non-human primates against the purified toxins produced by ... orogastric spore infection, a laboratory model that mimics the ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2
... the revolutionary scientific journal that pairs peer-reviewed scholarly text ... submissions are now open for JoVE Behavior, ... section will enable scientists studying behavior to publish cutting ... this scientific field to new levels of productivity, reproducibility ...
... bacteria inside squids use light and chemical signals to control ... be published on April 2 in mBio , the ... Hawaiian bobtail squid, Euprymna scolopes , houses a colony ... using the bacteria at night as an antipredatory camouflage while ...
... April 1, 2013 California sagebrush in the southern ... change than sagebrush populations in the north, according to ... Evolutionary Biology affiliated with the Center for Environmental Biology. ... in Global Change Biology , will assist land ...
Cached Biology News:Symbiotic bacteria program daily rhythms in squid using light and chemicals 2Symbiotic bacteria program daily rhythms in squid using light and chemicals 3Southern California sagebrush better suited to climate change, UCI study finds 2
Rabbit polyclonal to Retinoic Acid Receptor beta 2 ( Abpromise for all tested applications). entrezGeneID: 5915...
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
...
... affinity media for spontaneous ligand immobilization can be ... enzyme, antigen, or receptor to create an affinity ... supports couple ligands via primary amines. Affi-Gel 10 ... from 6.5 to 11; Affi-Gel 15 gel couples ...
Biology Products: